[67] developed a nanoplatform that utilizes high concentrations of ROS and intestinal enzymes in the colon to pinpoint sites of inflammation, which has been shown to be effective in reducing systemic drug exposure and adverse effects
Secondary prevention of cardiovascular disease in high-risk patients diagnosed with cardiovascular disease (status post myocardial infarction or stroke, peripheral arterial disease), type 2 diabetes, or moderate to severe chronic kidney disease (CKD 4-5): in patients who cannot be diagnosed with FH according to Dutch criteria, although they have lipid disorders and do not achieve their LDL-C targets, according to the adopted guidelines (), and in whom all other standard therapies have failed (for at least 3 months) or are poorly tolerated, and/or there are contraindications to pharmacological treatment (adverse effects, complications, e.g
Unfortunately, those led to reports of cardiovascular events
E.RinconN.McCartyP
Mechanistic investigations have explored how BPC-157 interacts with vascular signaling systems such as VEGFR2-associated pathways and nitric oxiderelated signaling networks
The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies
